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Abstract
AIM—Differential migration and choice of denominator have been hypothesized to contribute to 
differences between period prevalence and birth prevalence of cerebral palsy (CP). The purpose of 
this study was to evaluate the effects of migration and choice of denominator on the prevalence of 
CP.
METHOD—Data from the Metropolitan Atlanta Developmental Disabilities Surveillance 
Program and census and birth certificate files were used to calculate various CP prevalence 
estimates for 2000.
RESULTS—The overall CP period prevalence was 3.2 (95% confidence interval [CI] 2.7–3.8) 
per 1000 8-year-olds and was similar for those born in Atlanta who resided there at age 8 years 
(3.3; 95% CI 2.7–4.1) and those born outside Atlanta who moved into Atlanta by age 8 years (3.0; 
95% CI 2.3–3.9). CP prevalence in these two migration strata was similar by sex and race/
ethnicity. CP birth prevalence of 8-year-olds in Atlanta in 2000 was 2.0 (95% CI 1.6–2.5) per 
1000 live births in 1992.
INTERPRETATION—The authors found no evidence to support the hypothesis that differential 
in-migration explained higher period than birth prevalence of CP in Atlanta. Comparability of CP 
prevalence across geographic areas will be enhanced if future studies report both period and birth 
prevalence.
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Data on the prevalence of cerebral palsy (CP) are used to plan for the service and resource 
needs of individuals with CP and may identify opportunities to prevent or reduce the 
severity of CP. CP prevalence is estimated by population-based registries and surveillance 
systems in many countries, but methods for calculating prevalence vary, making 
comparisons difficult.1 Although CP is often not diagnosed until after the age of 2 years,2,3 a 
common method of estimating CP prevalence is to use birth cohort denominators and 
compute prevalence as the number of children with CP per 1000 live births. We refer to 
estimates based on this method as birth prevalence. Population-based registries in Europe, 
Australia, and the United States have used this method and consistently find CP prevalence 
to be approximately 2 per 1000 live births.4–6 For these registries and surveillance programs, 
CP case status is not confirmed until age 4, 5, or 8 years.4–10 As a result, the birth 
prevalence numerator and denominator are enumerated at different times, often several years 
apart. If children who migrated from their birthplace or died before case confirmation are 
excluded from the birth prevalence numerator, but not the denominator, birth prevalence 
will be underestimated.
Studies in other parts of the world, including the United States, frequently report prevalence 
per 1000 children residing in a given geographic area during a given period, regardless of 
birthplace. These estimates, referred to as period prevalence, use census data for the 
denominator and yield generally higher prevalence estimates.7–13 For example, the 
Metropolitan Atlanta Developmental Disabilities Surveillance Program (MADDSP), a 
population-based, multiple-source, active surveillance system in the United States, has 
consistently reported CP period prevalence estimates of approximately 3 to 4 per 1000 8-
year-olds. This is nearly 50% higher than most birth prevalence estimates, including birth 
prevalence estimates reported by the same system.6–10 By using children compared with live 
births as the denominator, the period prevalence numerator and denominator are ascertained 
at the same point in time and are, therefore, subject to the same survival and migration 
effects. Many factors, in addition to denominator choice, may contribute to variations in CP 
prevalence across monitoring programs, including methodological differences in case 
ascertainment as well as varied levels of perinatal risk. However, it has been suggested that 
the higher period prevalence estimates in Atlanta may be partially or wholly attributable to 
selective in-migration of families of children with CP, perhaps for services, and the choice 
of children compared with live births as the denominator.14,15
The purpose of this paper is twofold: (1) to assess whether CP prevalence was higher among 
8-year-olds who migrated into Atlanta compared with children who were born in Atlanta 
and still resided there at age 8 years; and (2) to evaluate the choice of denominator on CP 
prevalence in Atlanta.
METHOD
For this analysis, CP period prevalence is the number of 8-year-olds with CP among all 8-
year-olds living in Atlanta, Georgia, during 2000. CP period prevalence has two 
components: (1) non-migrant period prevalence, the number of children with CP among 
children who have resided in Atlanta since birth (1992); and (2) in-migrant period 
prevalence, the number of children with CP among children who migrated into Atlanta after 
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birth (1992). CP birth prevalence is the number of 8-year-olds with CP among 1992 live 
births or live births who survived to 1 year of age. The components of birth prevalence are: 
(1) non-migrant birth prevalence, the number of children with CP among children born in 
Atlanta in 1992 who still lived there in 2000; (2) out-migrant birth prevalence, the number 
of children with CP among children who moved out of Atlanta after birth (1992); and (3) the 
number of children with CP among children who died between birth or 1 year of age and 
2000.
Numerator data
Data for the number of 8-year-olds with CP living in Atlanta in 2000 were obtained from 
MADDSP. In 2000, MADDSP monitored CP in five counties (Clayton, Cobb, DeKalb, 
Fulton, Gwinnett) in metropolitan Atlanta. For surveillance purposes, CP is defined as a 
group of non-progressive, but often changing, motor impairment syndromes secondary to 
lesions or anomalies of the brain arising at any time during brain development.16 The case 
definition by Mutch et al16 was modified to include children with a brain-damaging event 
after 28 days of life (postneonatal CP).7–10 A CP case was defined as a child born in 1992 
who resided in Atlanta during 2000 and who had a documented diagnosis of CP or physical 
findings consistent with CP in an evaluation by a qualified professional at or after age 2 
years. Children aged 8 years in 2000 suspected of having CP were identified by screening 
and abstracting evaluations at multiple educational and health sources. Data were abstracted 
into one composite record per child and reviewed by trained clinicians using a specified 
protocol to determine whether the identified children met the CP surveillance case 
definition. Case ascertainment, clinician review, and quality assurance details have been 
reported elsewhere.7–10 Children with CP were linked to birth and death vital statistics 
records to identify maternal county of residence at the time of the child’s birth and to 
exclude those children with CP who died before the surveillance year.
Period prevalence numerator—Data on birthplace were used to stratify 8-year-olds 
with CP living in Atlanta in 2000 by migration status. The numerator for period prevalence 
(n=135) comprised both non-migrant (n=82) and in-migrant (n=53) children with CP, 
including those with postneonatally acquired CP (n=12: five non-migrants, seven in-
migrants).
Birth prevalence numerator—The numerator for birth prevalence included non-migrant 
children with congenital CP (n=77). Non-migrant children with postneonatally acquired CP 
(n=5) were excluded. Data on cases of CP among children who died or migrated out of 
Atlanta between 1992 and 2000 were not available.
Denominator data
Period prevalence denominator—Data on the number of 8-year-olds living in Atlanta 
in 2000 were obtained from the US Census Public Use Microdata Set (PUMS).17 PUMS 
data were obtained from a 5% sample of census respondents and included several questions 
not included in the overall census. Respondents were asked whether they were born in 
Georgia and if they had lived at the same address on 1 April 1995, 5 years prior to the 
census date of 1 April 2000. Therefore, although decennial, intercensal, and postcensal 
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estimates are typically used for the MADDSP prevalence estimates,7–10,18 the additional 
PUMS information allowed us to stratify 8-year-olds living in Atlanta in 2000 (n=42 579) 
into non-migrants and in-migrants in order to correspond as closely as possible to the 
stratification of the numerator data. Non-migrants were defined as 8-year-olds born in 
Georgia who resided in Atlanta in 2000 and on 1 April 1995 (n=24 974). The number of in-
migrant children (n=17 615) was obtained by subtracting the number of non-migrant 
children from the total number of 8-year-olds living in Atlanta in 2000. The PUMS data 
include state of birth, but not birthplace, at the county level, and the residency questions 
covered only 5 years prior to the census. Thus, the non-migrant denominator is an 
overestimate since it includes children born in Georgia outside Atlanta who moved to 
Atlanta before 1 April 1995 and the in-migrant denominator is an underestimate since it 
excludes children born in Georgia outside of Atlanta who migrated into Atlanta before 1 
April 1995.
Birth prevalence denominator—Data on all 1992 Atlanta live births (n=38 195) were 
available from the Georgia Bureau of Vital Statistics. From linkage of the live birth and 
infant death files, we obtained the count of 1992 Atlanta live births surviving to 1 year of 
age (n=37 852).
Sociodemographic and clinical characteristics of children with CP
We stratified period prevalence estimates by sex and race/ ethnicity. We also compared 
selected characteristics of non-migrant and in-migrant children with CP, including sex, race/
ethnicity, census area median household income, CP subtype, and co-occurring 
developmental disabilities (intellectual disability, autism spectrum disorder, hearing loss, 
vision impairment), and a documented diagnosis of CP. The results for racial/ethnic groups 
other than White non-Hispanic and Black non-Hispanic were not presented because of small 
numbers. Children with CP were linked to block group data from the 2000 United States 
decennial census to obtain information on median household income, a proxy for socio-
economic status. The 95% confidence intervals (CIs) were calculated using the Poisson 
approximation to the binomial distribution. Differences in proportions were calculated using 
χ2 tests with a binomial distribution and p-value set at <0.05.
MADDSP functions as a public health authority under the Health Insurance Portability and 
Accountability Act of 1996 (HIPAA) Privacy Rule and met applicable Institutional Review 
Board and privacy/confidentiality requirements.
RESULTS
For MADDSP (2000), the overall period prevalence of CP was 3.2 (95% CI 2.7–3.8) per 
1000 8-year-olds (Fig. 1), calculated as a weighted average of non-migrant and in-migrant 
period prevalence. The non-migrant CP period prevalence of 3.3 (95% CI 2.7–4.1) per 1000 
was not statistically different from the in-migrant CP period prevalence of 3.0 (95% CI 2.3–
3.9) per 1000.
Among children with CP, male-to-female prevalence ratios (PRs) were similar among non-
migrant (PR 1.6; 95% CI 1.0–2.5) and in-migrant children (PR 1.3; 95% CI 0.7–2.2). 
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Prevalence ratios of Black non-Hispanic to White non-Hispanic children were also similar 
among non-migrants (PR 1.5; 95% CI 1.0–2.4) and in-migrants (PR 1.1; 95% CI 0.6–2.0; 
Table I). Non-migrant and in-migrant children with CP had similar distributions of low, 
middle, and high socio-economic status. Just over 80% of non-migrant children had spastic 
CP, compared with 70% of in-migrant children (p=0.34). Approximately 60% of non-
migrant and in-migrant children had at least one co-occurring developmental disability. 
Nearly all had a documented CP diagnosis, regardless of migration status (98–99%).
We calculated birth prevalence using non-migrant children with congenital CP (n=77) and 
1992 live births (n=38 195). This yielded a prevalence of 2.0 (95% CI 1.6–2.5) per 1000 live 
births, which was unchanged when 1-year survivors were used in the denominator. This 
estimate of CP birth prevalence does not include CP cases among out-migrant children or 
childhood deaths owing to lack of available data. Therefore, in an attempt to approximate 
the portion of the 1992 birth cohort that remained in Atlanta, we restricted the numerator to 
non-migrant children with congenital CP (n=77) and the denominator to non-migrant 8-year-
olds (n=24 962). This resulted in a prevalence estimate of 3.1 (95% CI 2.5–3.9), which was 
substantially higher than the prevalence obtained using live births in the denominator.
DISCUSSION
It has been hypothesized that differential migration patterns can cause period prevalence to 
be higher than birth prevalence in communities where availability of high-quality education 
and clinical resources for children with developmental disabilities influences a family’s 
decision to move into a specific geographic area after birth.14,15 We found no evidence that 
CP prevalence differed for children who moved into Atlanta compared with those who were 
born in and remained in Atlanta. In addition, in-migrant children with CP were similar to 
non-migrant children with CP by demographic variables, CP subtype, and presence of a co-
occurring developmental disability. These results are not consistent with the hypothesis that 
the higher CP prevalence reported by MADDSP results only from selective in-migration of 
children with CP seeking services. It is possible that families migrating out of Atlanta are 
less likely than those remaining in Atlanta to have a child with CP, leaving a population that 
is relatively enriched for CP. The difference between birth prevalence and period prevalence 
was at least partially explained by the underestimation of birth prevalence as calculated 
using only non-migrant cases among all 1992 live births.
The use of a live birth denominator is predicated on the etiology of and risk factors for CP 
occurring from the pre-natal period through the first few years of life.14 Although this risk 
period is reasonable, given the likely prenatal or perinatal origin of most CP cases, case 
confirmation for CP registries and surveillance programs occurs later in childhood; more 
specifically at age 8 years for the MAD-DSP and age 4 or 5 years for surveillance programs 
in Europe and Australia.5–10 Case confirmation after age 4 years may avoid inclusion of 
children whose earlier motor findings or impairment(s) owing to progressive disorders do 
not subsequently meet CP criteria.2,3 The extended interval between the period of risk and 
the time of CP confirmation gives ample time for children with CP to migrate out of the 
original birth cohort. Therefore, accurate calculation of birth prevalence requires the ability 
to identify all children with CP who died or migrated out of the birth cohort’s geographical 
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area prior to case confir-mation age. Underestimation will occur if these children are not 
counted and a fixed live birth or 1-year-survivor denominator is used.
We tried to better estimate birth prevalence by restricting the denominator to non-migrant 
children, the portion of the 1992 birth cohort that remained in Atlanta, to correspond with 
the non-migrant cases in the numerator. The resulting estimate of 3.1 per 1000 was 
substantially higher than the estimate using all live births. This would be a valid estimate of 
birth prevalence if CP prevalence among out-migrant children was similar to CP prevalence 
among non-migrant children. However, CP prevalence among non-migrant children could 
be higher than prevalence among out-migrant children if families of children with CP are 
more likely to remain in Atlanta than families of children without CP.
We conducted a sensitivity analysis (Appendix) to examine how low out-migrant CP 
prevalence would need to be to result in a birth prevalence of approximately 2 per 1000. We 
estimated a denominator of out-migrants (n=13 231) from this birth cohort by subtracting 
non-migrant children estimated by the PUMS (n=24 964) from the 1992 live births (n=38 
195), and set different values for CP prevalence among out-migrants, ranging from 0.5 to 
4.5 per 1000. The contribution of deaths was assumed to be negligible. Birth prevalence 
approached 2 per 1000 only when the CP prevalence among out-migrants was assumed to be 
extremely low – 0.5 cases per 1000 – with CP non-migrant prevalence of approximately 3 
cases per 1000. The possibility of an inflated CP period prevalence due to families of 
children with CP being both more likely to stay and more likely to move into Atlanta 
suggests the need for research related to the impact of CP on families in the United States 
such as parents foregoing opportunities for advancement because of healthcare 
considerations.
Metropolitan Atlanta Developmental Disabilities Surveillance Program cerebral palsy period 
prevalence estimates are comparable with other United States estimates, ranging from 3.0 to 
4.0 per 1000 children (Table II).8–12 The most recent CP prevalence estimate from the 
National Health Interview Survey, a nationally representative sample of children from 3 
years through to 17 years of age, was 3.9 per 1000 children.12 This survey, based on parental 
report, was a random sample of the United States non-institutionalized population and, 
therefore, unlikely to have been subject to the differential migration suggested to occur in 
Atlanta. Although parents of young children with an early suspicion of CP may have 
responded positively despite lack of confirmation of a CP diagnosis, we do not believe that 
this possible over-reporting would account for an overall increase of approximately 1 per 
1000.
Another example of consistent period prevalence estimates is from the Autism and 
Developmental Disabilities Monitoring (ADDM) Network, which monitors CP prevalence 
in the United States using MADDSP methods. Period prevalence estimates from this 
network range from 2.7 to 3.3 per 1000 8-year-olds.8–10 Not all ADDM sites were solely in 
urban areas, so differential in-migration or residential stability owing to the presence of 
high-quality developmental disability services was less likely to have been a factor for 
period prevalence. Even when the proportion of in-migrant CP cases was low, such as 
approximately 20% in Alabama, prevalence based on live births was substantially lower 
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than prevalence based on census data (Table II). This suggests that the inability to include 
the number of out-migrant CP cases or those that died contributed to artificially low birth 
prevalence estimates. Because the birth prevalence denominator reflects the entire 
underlying birth cohort while the numerator is restricted to non-migrant children only, birth 
prevalence data should be used cautiously to identify birth characteristics associated with 
CP. This issue of unknown out-migration is also applicable to registries outside the United 
States. The extent to which it contributes to the generally lower birth prevalence estimates, 
ranging from 1.5 to 2.6 per 1000 live births, compared with those in the United States is 
worthy of further exploration (Table II).
A limitation of our analysis is that the closest we could approximate the non-migrant period 
prevalence denominator was by subsetting 8-year-olds residing in Atlanta in 2000 to include 
those born in Georgia and living in Atlanta for the previous 5 years. We were not able to 
exclude, from the non-migrant denominator, children who were born elsewhere in the state 
of Georgia, outside of Atlanta, but who moved into Atlanta by age 3 years. Ideally, these 
children should have been reclassified and added to the 17 615 in-migrant children. 
Correcting for this misclassification would have resulted in a lower in-migrant CP 
prevalence. A lower in-migrant prevalence provides further support that the higher overall 
CP period prevalence is not entirely driven by higher prevalence CP among in-migrants than 
non-migrants. Our PUMS data may not be representative of the residency of all 8-year-olds 
in Atlanta in 1995; however, since the PUMS samples were selected at random, we assumed 
no systematic bias in migration information.
We found that in-migrant CP period prevalence did not differ from non-migrant CP period 
prevalence; however, they both may be higher than birth prevalence if children with CP are 
more likely to move into or stay in Atlanta after birth for financial reasons or because of 
concerns about access to services. Prevalence among live births was underestimated because 
of the inability to ascertain CP among children who died or moved out of Atlanta. Our 
sensitivity analyses indicated that out-migrant CP prevalence would have to be as low as 0.5 
per 1000 to result in an overall period prevalence approximating the observed birth 
prevalence. It is likely that the actual birth prevalence of CP in Atlanta is closer to 3 per 
1000, higher than birth prevalence from non-United States surveillance systems. To provide 
comparability among CP prevalence estimates in different geographical areas, we encourage 
other monitoring programs to consider calculating both period and birth prevalence. If 
period prevalence in the United States is found to be higher than period prevalence in other 
developed countries, then further examination of migration and survival patterns as well as 
differences in the distribution of risk factors across various populations could help to explain 
global differences in CP prevalence.
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What this paper adds
• Period prevalence of CP was similar among in-migrants and non-migrants; both 
significantly higher than birth prevalence.
• Consideration of migration and survival patterns is necessary to compare birth 
and period CP prevalence.
• Use of different denominators complicates comparison of CP prevalence 
estimates.
• Reporting both birth and period prevalence would enhance our understanding of 
CP prevalence worldwide.
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Role of migration on cerebral palsy (CP) period prevalence using data from the Metropolitan 
Atlanta Developmental Disabilities Surveillance Program (MADDSP) and US Census 
Public Use Microdata Sample (PUMS), 2000. *Includes children born in Georgia in 1992 
but outside of metropolitan (metro) Atlanta who moved into metro Atlanta by age 3 years. 
We were unable to classify these children into the in-migrant denominator.
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